Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2018

Open Access 01-02-2018 | Review

Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion

Authors: Sandro Giannini, Sandro Mazzaferro, Salvatore Minisola, Luca De Nicola, Maurizio Rossini, Mario Cozzolino

Published in: Endocrine | Issue 2/2018

Login to get access

Abstract

Vitamin D is recognized to play an essential role in health and disease. In kidney disease, vitamin D analogs have gained recognition for their involvement and potential therapeutic importance. Nephrologists are aware of the use of oral native vitamin D supplementation, however, uncertainty still exists with regard to the use of this treatment option in chronic kidney disease as well as clinical settings related to chronic kidney disease, where vitamin D supplementation may be an appropriate therapeutic choice. Two consecutive meetings were held in Florence in July and November 2016 comprising six experts in kidney disease (N = 3) and bone mineral metabolism (N = 3) to discuss a range of unresolved issues related to the use of cholecalciferol in chronic kidney disease. The panel focused on the following six key areas where issues relating to the use of oral vitamin D remain controversial: (1) vitamin D and parathyroid hormone levels in the general population, (2) cholecalciferol in chronic kidney disease, (3) vitamin D in cardiovascular disease, (4) vitamin D and renal bone disease, (5) vitamin D in rheumatological diseases affecting the kidney, (6) vitamin D and kidney transplantation.
Literature
1.
2.
X. Deng, Y. Song, J.E. Manson, L.B. Signorello, S.M. Zhang, M.J. Shrubsole, R.M. Ness, D.L. Seidner, Q. Dai, Magnesium, vitamin D status and mortality: results from US national health and nutrition examination survey (NHANES) 2001 to 2006 and NHANES III. BMC Med. 11, 187 (2013)PubMedPubMedCentralCrossRef
3.
A. Gorini, A.M. Costanzo, C.G. Egan, U. di Luzio, Paparatti, renal status in adult volunteers in central italy: results from family abbott renal disease monitoring project (FARM) study. J. Nephrol. 25, 523–532 (2012)PubMedCrossRef
4.
D.M. Freedman, A.C. Looker, S.-C. Chang, B.I. Graubard, Prospective study of serum vitamin D and cancer mortality in the United States. J. Natl. Cancer Inst. 99, 1594–1602 (2007)PubMedCrossRef
5.
S.R. Motiwala, T.J. Wang, Vitamin D and cardiovascular risk. Curr. Hypertens. Rep. 14, 209–218 (2012)PubMedCrossRef
6.
E.A. González, A. Sachdeva, D.A. Oliver, K.J. Martin, Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am. J. Nephrol. 24, 503–510 (2004)PubMedCrossRef
7.
D.J.A. Goldsmith, Z.A. Massy, V. Brandenburg, The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD). Semin. Nephrol. 34, 660–668 (2014)PubMedCrossRef
8.
9.
R. Krause, H.J. Roth, H. Kaase, R. Stange, M.F. Holick, Vitamin D Status in Chronic Kidney Disease - UVB Irradiation Is Superior to Oral Supplementation. Anticancer Res. 36, 1397–1401 (2016)PubMed
10.
M.J. Ala-Houhala, K. Vähävihu, E. Snellman, T. Hasan, H. Kautiainen, P. Karisola, Y. Dombrowski, J. Schauber, H. Saha et al., A narrow-band ultraviolet B course improves vitamin D balance and alters cutaneous CYP27A1 and CYP27B1 mRNA expression levels in hemodialysis patients supplemented with oral vitamin D. Nephron Clin. Pract. 124, 17–22 (2013)PubMedCrossRef
11.
M. Cozzolino, D. Brancaccio, G. Cannella, P. Messa, L. Gesualdo, M. Marangella, C. LoDeserto, M. Pozzato, G. Rombolà et al., VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey. Nephrol. Dial. Transplant. 27, 3588–3594 (2012)PubMedCrossRef
12.
S. Khan, Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am. J. Med. Sci. 333, 201–207 (2007)PubMedCrossRef
13.
14.
C. Cipriani, S. Piemonte, M. Cilli, J. Pepe, S. Minisola, Update on vitamin D: pros and cons. Clin. Cases Miner. Bone Metab. 12, 222–223 (2015)PubMedPubMedCentral
15.
C.S. Stokes, F. Lammert, Vitamin D supplementation: less controversy, more guidance needed. F1000Res. 5 (2016).
16.
A.S. Dusso, M. Tokumoto, Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int. 79, 715–729 (2011)PubMedCrossRef
17.
S. Mazzaferro, D. Goldsmith, T.E. Larsson, Z.A. Massy, M. Cozzolino, Vitamin D metabolites and/or analogs: which D for which patient? Curr. Vasc. Pharmacol. 12, 339–349 (2014)PubMedCrossRef
18.
J.A. Kellum, N. Lameire, P. Aspelin, R.S. Barsoum, E.A. Burdmann, S.L. Goldstein, C.A. Herzog, M. Joannidis, A. Kribben et al., Work group membership. Kidney Int. 2, 1 (2012)CrossRef
19.
National Kidney Foundation, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42, S1–S201 (2003)
20.
KDIGO 2016, (Mineral & bone disorder | KDIGO, 2016), http://​kdigo.​org/​home/​mineral-bone-disorder/​
21.
L.F. Morrone, P. Bolasco, C. Camerini, G. Cianciolo, A. Cupisti, A. Galassi, S. Mazzaferro, D. Russo, L. Russo et al., Vitamin D in patients with chronic kidney disease: a position statement of the Working Group “Trace Elements and Mineral Metabolism” of the Italian Society of Nephrology. J. Nephrol. 29, 305–328 (2016)PubMedCrossRef
22.
D. Pavlovic, D. Katicic, T. Gulin, J. Josipovic, Vitamin d in the patients with chronic kidney disease: when, to whom and in which form. Mater Socio-Medica 27, 122–124 (2015)CrossRef
23.
M. Cozzolino, J. Bover, M. Vervloet, V.M. Brandenburg, A multidisciplinary review of the science of vitamin D receptor activation. Kidney Int. Suppl. 1, 107–110 (2011)CrossRef
24.
E. Romagnoli, J. Pepe, S. Piemonte, C. Cipriani, S. Minisola, Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur. J. Endocrinol. 169, R59–R69 (2013)PubMedCrossRef
25.
S.A. Shapses, E.J. Lee, D. Sukumar, R. Durazo-Arvizu, S.H. Schneider, The effect of obesity on the relationship between serum parathyroid hormone and 25-hydroxyvitamin D in women. J. Clin. Endocrinol. Metab. 98, E886–890 (2013)PubMedPubMedCentralCrossRef
26.
J. Pepe, E. Romagnoli, I. Nofroni, M.T. Pacitti, S. De Geronimo, C. Letizia, G. Tonnarini, A. Scarpiello, E. D’Erasmo et al., Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjectsOsteoporos. Int. J. 16,805–812 (2005)CrossRef
27.
J.-C.Souberbielle, F.Brazier, M.-L.Piketty, C.Cormier, S.Minisola, E.Cavalier, How the reference values for serum parathyroid hormone concentration are (or should be) established? J. Endocrinol. Invest. 3, 241–256 (2016)
28.
C. Cipriani, E. Romagnoli, J. Pepe, S. Russo, L. Carlucci, S. Piemonte, L. Nieddu, D.J. McMahon, R. Singh et al., Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. J. Clin. Endocrinol. Metab. 98, 2709–2715 (2013)PubMedCrossRef
29.
A. Gal-Moscovici, S.M. Sprague, Use of vitamin D in chronic kidney disease patients. Kidney Int. 78, 146–151 (2010)PubMedCrossRef
30.
N.A. Dhayat, D. Ackermann, M. Pruijm, B. Ponte, G. Ehret, I. Guessous, A.B. Leichtle, F. Paccaud, M. Mohaupt et al., Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int. 90, 648–657 (2016)PubMedCrossRef
31.
M.W. Taal, V. Thurston, N.J. McIntyre, R.J. Fluck, C.W. McIntyre, The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney Int. 86, 407–413 (2014)PubMedCrossRef
32.
A. Valcour, F. Blocki, D.M. Hawkins, S.D. Rao, Effects of age and serum 25-OH-vitamin D on serum parathyroid hormone levels. J. Clin. Endocrinol. Metab. 97, 3989–3995 (2012)PubMedCrossRef
33.
R. Vieth, G.El-Hajj Fuleihan, There is no lower threshold level for parathyroid hormone as 25-hydroxyvitamin D concentrations increase. J. Endocrinol. Invest. 28, 183–186 (2005)PubMedCrossRef
34.
R.P. Heaney, Serum 25-hydroxyvitamin D and parathyroid hormone exhibit threshold behavior. J. Endocrinol. Invest. 28, 180–182 (2005)PubMedCrossRef
35.
J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman, C. Marcocci, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014)PubMedPubMedCentralCrossRef
36.
S.J. Silverberg, B.L. Clarke, M. Peacock, F. Bandeira, S. Boutroy, N.E. Cusano, D. Dempster, E.M. Lewiecki, J.-M. Liu et al., Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3580–3594 (2014)PubMedPubMedCentralCrossRef
37.
M. Touvier, M. Deschasaux, M. Montourcy, A. Sutton, N. Charnaux, E. Kesse-Guyot, L.K. Fezeu, P. Latino-Martel, N. Druesne-Pecollo et al., Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J. Clin. Endocrinol. Metab. 99, 1196–1203 (2014)PubMedCrossRef
38.
R. Eastell, M.L. Brandi, A.G. Costa, P. D’Amour, D.M. Shoback, R.V. Thakker, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J. Clin. Endocrinol. Metab. 99, 3570–3579 (2014)PubMedCrossRef
39.
J.-C. Souberbielle, C. Massart, S. Brailly-Tabard, C. Cormier, E. Cavalier, P. Delanaye, P. Chanson, Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients. Eur. J. Endocrinol. 174, 315–323 (2016)PubMedCrossRef
40.
N.H. Bell, 25-Hydroxyvitamin D3 reverses alteration of the vitamin D-endocrine system in blacks. Am. J. Med. 99, 597–599 (1995)PubMedCrossRef
41.
C. Cipriani, J. Pepe, S. Piemonte, L. Colangelo, M. Cilli, S. Minisola, Vitamin d and its relationship with obesity and muscle. Int. J. Endocrinol. 2014, 841248 (2014)PubMedPubMedCentralCrossRef
42.
S. Minisola, M.T. Pacitti, A. Scarda, R. Rosso, E. Romagnoli, V. Carnevale, L. Scarnecchia, G.F. Mazzuoli, Serum ionized calcium, parathyroid hormone and related variables: effect of age and sex. Bone Miner. 23, 183–193 (1993)PubMedCrossRef
43.
P. Ravani, F. Malberti, G. Tripepi, P. Pecchini, S. Cutrupi, P. Pizzini, F. Mallamaci, C. Zoccali, Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 75, 88–95 (2009)PubMedCrossRef
44.
S. Pilz, S. Iodice, A. Zittermann, W.B. Grant, S. Gandini, Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am. J. Kidney Dis. 58, 374–382 (2011)PubMedCrossRef
45.
C. Drechsler, M. Verduijn, S. Pilz, F.W. Dekker, R.T. Krediet, E. Ritz, C. Wanner, E.W. Boeschoten, V. Brandenburg et al., Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol. Dial. Transplant. 26, 1024–1032 (2011)PubMedCrossRef
46.
P. Molina, J.L. Górriz, M.D. Molina, S. Beltrán, B. Vizcaíno, V. Escudero, J. Kanter, A.I. Ávila, J. Bover et al., What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? World J. Nephrol. 5, 471–481 (2016)PubMedPubMedCentralCrossRef
47.
P. Kandula, M. Dobre, J.D. Schold, M.J. Schreiber, R. Mehrotra, S.D. Navaneethan, Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol. 6, 50–62 (2011)PubMedPubMedCentralCrossRef
48.
S. Moe, T. Drüeke, J. Cunningham, W. Goodman, K. Martin, K. Olgaard, S. Ott, S. Sprague, N. Lameire et al., Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 69, 1945–1953 (2006)PubMedCrossRef
49.
P. Marckmann, H. Agerskov, S. Thineshkumar, E.-M. Bladbjerg, J.J. Sidelmann, J. Jespersen, M. Nybo, L.M. Rasmussen, D. Hansen et al., Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol. Dial. Transplant. 27, 3523–3531 (2012)PubMedCrossRef
50.
J.A. Alvarez, J. Law, K.E. Coakley, S.M. Zughaier, L. Hao, K. Shahid Salles, H. Wasse, O.M. Gutiérrez, T.R. Ziegler et al., High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 96, 672–679 (2012)PubMedPubMedCentralCrossRef
51.
P.J. Matias, C. Jorge, C. Ferreira, M. Borges, I. Aires, T. Amaral, C. Gil, J. Cortez, A. Ferreira, Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin. J. Am. Soc. Nephrol. 5, 905–911 (2010)PubMedPubMedCentralCrossRef
52.
P. Ruggenenti, E. Perticucci, P. Cravedi, V. Gambara, M. Costantini, S.K. Sharma, A. Perna, G. Remuzzi, Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213–1224 (2008)PubMedPubMedCentralCrossRef
53.
S. Borrelli, D. Leonardis, R. Minutolo, P. Chiodini, L. De Nicola, C. Esposito, F. Mallamaci, C. Zoccali, G. Conte, Epidemiology of CKD regression in patients under nephrology care. PLoS One 10, e0140138 (2015)PubMedPubMedCentralCrossRef
54.
L. De Nicola, P. Chiodini, C. Zoccali, S. Borrelli, B. Cianciaruso, B. Di Iorio, D. Santoro, V. Giancaspro, C. Abaterusso et al., Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin. J. Am. Soc. Nephrol. 6, 2421–2428 (2011)PubMedPubMedCentralCrossRef
55.
L. De Nicola, M. Provenzano, P. Chiodini, S. Borrelli, C. Garofalo, M. Pacilio, M.E. Liberti, A. Sagliocca, G. Conte et al., Independent role of underlying kidney disease on renal prognosis of patients with chronic kidney disease under nephrology care. PLoS One 10, e0127071 (2015)PubMedPubMedCentralCrossRef
56.
57.
R. Agarwal, Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects? Kidney Int. 77, 943–945 (2010)PubMedCrossRef
58.
R. Agarwal, M. Acharya, J. Tian, R.L. Hippensteel, J.Z. Melnick, P. Qiu, L. Williams, D. Batlle, Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 68, 2823–2828 (2005)PubMedCrossRef
59.
D. de Zeeuw, R. Agarwal, M. Amdahl, P. Audhya, D. Coyne, T. Garimella, H.-H. Parving, Y. Pritchett, G. Remuzzi et al., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet 376, 1543–1551 (2010)PubMedCrossRef
60.
L.-J. Liu, J.-C. Lv, S.-F. Shi, Y.-Q. Chen, H. Zhang, H.-Y. Wang, Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am. J. Kidney Dis. 59, 67–74 (2012)PubMedCrossRef
61.
L. De Nicola, G. Conte, D. Russo, A. Gorini, R. Minutolo, Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. BMC Nephrol. 13, 150 (2012)PubMedPubMedCentralCrossRef
62.
E. Riccio, M. Sabbatini, D. Bruzzese, I. Capuano, S. Migliaccio, M. Andreucci, A. Pisani, Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS One 10, e0118174 (2015)PubMedPubMedCentralCrossRef
63.
M.J. Kim, A.H. Frankel, M. Donaldson, S.J. Darch, C.D. Pusey, P.D. Hill, M. Mayr, F.W.K. Tam, Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int. 80, 851–860 (2011)PubMedCrossRef
64.
Y. Huang, H. Yu, J. Lu, K. Guo, L. Zhang, Y. Bao, H. Chen, W. Jia, Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy. PLoS One 7, e50510 (2012)PubMedPubMedCentralCrossRef
65.
P. Molina, J.L. Górriz, M.D. Molina, A. Peris, S. Beltrán, J. Kanter, V. Escudero, R. Romero, L.M. Pallardó, The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study. Nephrol. Dial. Transplant. 29, 97–109 (2014)PubMedCrossRef
66.
O. García-Sánchez, F.J. López-Hernández, J.M. López-Novoa, An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int. 77, 950–955 (2010)PubMedCrossRef
67.
L. De Nicola, F. Locatelli, G. Conte, R. Minutolo, Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? Drugs 74, 159–168 (2014)PubMedCrossRef
68.
J.A. Kellum, N. Lameire, P. Aspelin, R.S. Barsoum, E.A. Burdmann, S.L. Goldstein, C.A. Herzog, M. Joannidis, A. Kribben et al., KDIGO 2012. Kidney Int. 2, 1 (2012)CrossRef
69.
R. Minutolo, G. Conte, B. Cianciaruso, V. Bellizzi, A. Camocardi, L. De Paola, L. De Nicola, Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol. Dial. Transplant. 27, 2880–2886 (2012)PubMedCrossRef
70.
J. Luo, D.E. Jensen, B.J. Maroni, S.M. Brunelli, Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients. Am. J. Kidney Dis. 68, 763–771 (2016)PubMedCrossRef
71.
S. Albitar, R. Genin, M. Fen-Chong, M.O. Serveaux, D. Schohn, C. Chuet, High-dose alfacalcidol improves anemia in patients on hemodialysis. Nephrol. Dial. Transplant. 12, 514–518 (1997)PubMedCrossRef
72.
N.M. Patel, O.M. Gutiérrez, D.L. Andress, D.W. Coyne, A. Levin, M. Wolf, Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int. 77, 715–720 (2010)PubMedCrossRef
73.
A. Icardi, E. Paoletti, L. De Nicola, S. Mazzaferro, R. Russo, M. Cozzolino, Renal anemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol. Dial. Transplant. 28, 1672–1679 (2013)PubMedCrossRef
74.
B. Afsar, E. Agca, S. Turk, Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol. J. Clin. Pharmacol. 55, 1280–1285 (2015)PubMedCrossRef
75.
J. Bacchetta, J.J. Zaritsky, J.L. Sea, R.F. Chun, T.S. Lisse, K. Zavala, A. Nayak, K. Wesseling-Perry, M. Westerman et al., Suppression of iron-regulatory hepcidin by vitamin D. J. Am. Soc. Nephrol. 25, 564–572 (2014)PubMedCrossRef
76.
D.C. Miskulin, K. Majchrzak, H. Tighiouart, R.S. Muther, T. Kapoian, D.S. Johnson, D.E. Weiner, Ergocalciferol supplementation in hemodialysis patients with vitamin d deficiency: a randomized clinical trial. J. Am. Soc. Nephrol. 27, 1801–1810 (2016)PubMedCrossRef
77.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), Kidney Int. Suppl. 76 (Suppl. 113), S1–130 (2009)
78.
A.Y.-M. Wang, F. Fang, J. Chan, Y.-Y. Wen, S. Qing, I.H.-S. Chan, G. Lo, K.-N. Lai, W.-K. Lo et al., Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. J. Am. Soc. Nephrol. 25, 175–186 (2014)PubMedCrossRef
79.
R. Thadhani, E. Appelbaum, Y. Pritchett, Y. Chang, J. Wenger, H. Tamez, I. Bhan, R. Agarwal, C. Zoccali et al., Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307, 674–684 (2012)PubMedCrossRef
80.
X.-H.Li, L.Feng, Z.-H.Yang, Y.-H.Liao, The effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis. Nephrology 20, 706–714 (2015)CrossRef
81.
L. Xu, X. Wan, Z. Huang, F. Zeng, G. Wei, D. Fang, W. Deng, Y. Li, Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials. PLoS One 8, e61387 (2013)PubMedPubMedCentralCrossRef
82.
A. Massart, F.D. Debelle, J. Racapé, C. Gervy, C. Husson, M. Dhaene, K.M. Wissing, J.L. Nortier, Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial. Am. J. Kidney Dis. 64, 696–705 (2014)PubMedCrossRef
83.
V. Tangpricha, H. Wasse, Vitamin D therapy in kidney disease: more vitamin D is necessary. Am. J. Kidney Dis. 64, 667–669 (2014)PubMedCrossRef
84.
J. Alvarez, H. Wasse, V. Tangpricha, Vitamin D supplementation in pre-dialysis chronic kidney disease: a systematic review. Dermatoendocrinology 4, 118–127 (2012)CrossRef
85.
G. Jones, Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs. Semin. Dial. 23, 239–243 (2010)PubMedCrossRef
86.
S. Dusilová-Sulková, R. Šafránek, J. Vávrová, J. Horáček, L. Pavlíková, V. Palička, Low-dose cholecalciferol supplementation and dual vitamin D therapy in hemodialysis patients. Int. Urol. Nephrol. 47, 169–176 (2015)PubMedCrossRef
87.
D. Santoro, D. Caccamo, S. Lucisano, M. Buemi, K. Sebekova, D. Teta, L. De Nicola, Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system. BioMed Res. Int. 2015, 145828 (2015)PubMedPubMedCentral
88.
Y.C. Li, J. Kong, M. Wei, Z.-F. Chen, S.Q. Liu, L.-P. Cao, 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110, 229–238 (2002)PubMedPubMedCentralCrossRef
89.
W. Xiang, J. Kong, S. Chen, L.-P. Cao, G. Qiao, W. Zheng, W. Liu, X. Li, D.G. Gardner et al., Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 288, E125–132 (2005)PubMedCrossRef
90.
91.
J.N. Artaza, R. Mehrotra, K.C. Norris, Vitamin D and the cardiovascular system. Clin.J. Am. Soc. Nephrol. 4, 1515–1522 (2009)PubMedCrossRef
92.
R. Mehrotra, D.A. Kermah, I.B. Salusky, M.S. Wolf, R.I. Thadhani, Y.-W. Chiu, D. Martins, S.G. Adler, K.C. Norris, Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 76, 977–983 (2009)PubMedPubMedCentralCrossRef
93.
I.H. de Boer, G.N. Ioannou, B. Kestenbaum, J.D. Brunzell, N.S. Weiss, 25-hydroxyvitamin D levels and albuminuria in the third national health and nutrition examination survey (NHANES III). Am. J. Kidney Dis. 50, 69–77 (2007)PubMedCrossRef
94.
J.P. Forman, E. Giovannucci, M.D. Holmes, H.A. Bischoff-Ferrari, S.S. Tworoger, W.C. Willett, G.C. Curhan, Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063–1069 (2007)PubMedCrossRef
95.
A.G. Pittas, B. Dawson-Hughes, T. Li, R.M. Van Dam, W.C. Willett, J.E. Manson, F.B. Hu, Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29, 650–656 (2006)PubMedCrossRef
96.
E. Theodoratou, I. Tzoulaki, L. Zgaga, J.P.A. Ioannidis, Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyzes of observational studies and randomized trials. BMJ 348, g2035 (2014)PubMedPubMedCentralCrossRef
97.
M. Wolf, A. Shah, O. Gutierrez, E. Ankers, M. Monroy, H. Tamez, D. Steele, Y. Chang, C.A. Camargo et al.,. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72, 1004–1013 (2007)PubMedCrossRef
98.
K.O. Kilickesmez, O. Abaci, B. Okcun, C. Kocas, M. Baskurt, A. Arat, M. Ersanli, T. Gurmen, Chronic kidney disease as a predictor of coronary lesion morphology. Angiology 61, 344–349 (2010)PubMedCrossRef
99.
R.M. Holden, A.R. Morton, J.S. Garland, A. Pavlov, A.G. Day, S.L. Booth, Vitamins K and D status in stages 3-5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 590–597 (2010)PubMedPubMedCentralCrossRef
100.
S. Fishbane, H. Chittineni, M. Packman, P. Dutka, N. Ali, N. Durie, Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am. J. Kidney Dis. 54, 647–652 (2009)PubMedCrossRef
101.
R. Agarwal, Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD, Clin. J. Am. Soc. Nephrol. 4, 1523–1528 (2009)CrossRef
102.
R. Scragg, M. Sowers, C. Bell, Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. Am. J. Hypertens. 20, 713–719 (2007)PubMedCrossRef
103.
M. Pfeifer, B. Begerow, H.W. Minne, D. Nachtigall, C. Hansen, Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 86, 1633–1637 (2001)PubMed
104.
J.P. Forman, J.B. Scott, K. Ng, B.F. Drake, E.G. Suarez, D.L. Hayden, G.G. Bennett, P.D. Chandler, B.W. Hollis et al., Effect of vitamin D supplementation on blood pressure in blacks. Hypertension 61, 779–785 (2013)PubMedPubMedCentralCrossRef
105.
T. Larsen, F.H. Mose, J.N. Bech, A.B. Hansen, E.B. Pedersen, Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. Am. J. Hypertens. 25, 1215–1222 (2012)PubMedCrossRef
106.
R. Krause, M. Bühring, W. Hopfenmüller, M.F. Holick, A.M. Sharma, Ultraviolet B and blood pressure. Lancet 352, 709–710 (1998)PubMedCrossRef
107.
G. Bjelakovic, LL. Gluud, D. Nikolova, K. Whitfield, J. Wetterslev, RG. Simonetti, M. Bjelakovic, C. Gluud,Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev. 7, CD007470 (2014)
108.
J. Bover, P. Ureña, V. Brandenburg, D. Goldsmith, C. Ruiz, I. DaSilva, R.J. Bosch, Adynamic bone disease: from bone to vessels in chronic kidney disease. Semin. Nephrol. 34, 626–640 (2014)PubMedCrossRef
109.
P.U. Torres, J. Bover, S. Mazzaferro, M.C. de Vernejoul, M. Cohen-Solal, When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin. Nephrol. 34, 612–625 (2014)PubMedCrossRef
110.
J.B. Cannata-Andía, M. Rodriguez García, C. Gómez Alonso, Osteoporosis and adynamic bone in chronic kidney disease. J. Nephrol. 26, 73–80 (2013)PubMedCrossRef
111.
S.L. West, C.E. Lok, L. Langsetmo, A.M. Cheung, E. Szabo, D. Pearce, M. Fusaro, R. Wald, J. Weinstein et al., Bone mineral density predicts fractures in chronic kidney disease. J. Bone Miner. Res. 30, 913–919 (2015)PubMedCrossRef
112.
T.B. Drüeke, Z.A. Massy, Changing bone patterns with progression of chronic kidney disease. Kidney Int. 89, 289–302 (2016)PubMedCrossRef
113.
D.J.A. Goldsmith, Pro: should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol. Dial. Transplant 31, 698–705 (2016)PubMedCrossRef
114.
R. Agarwal, P.I. Georgianos, Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol. Dial. Transplant. 31, 706–713 (2016)PubMedCrossRef
115.
C. Zoccali, F. Mallamaci, Moderator’s view: vitamin D deficiency treatment in advanced chronic kidney disease: a close look at the emperor’s clothes. Nephrol. Dial. Transplant. 31, 714–716 (2016)PubMedCrossRef
116.
H.H. Malluche, H.W. Mawad, M.-C. Monier-Faugere, Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J. Bone Miner. Res. 26, 1368–1376 (2011)PubMedCrossRef
117.
S.M. Sprague, E. Bellorin-Font, V. Jorgetti, A.B. Carvalho, H.H. Malluche, A. Ferreira, P.C. D’Haese, T.B. Drüeke, H. Du et al., Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am. J. Kidney Dis. 67, 559–566 (2016)PubMedCrossRef
118.
F.C. Barreto, D.V. Barreto, M.E.F. Canziani, C. Tomiyama, A. Higa, A. Mozar, G. Glorieux, R. Vanholder, Z. Massy et al., Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. J. Bras. Nefrol 36, 289–296 (2014)PubMed
119.
G. Coen, S. Mazzaferro, P. Ballanti, D. Sardella, S. Chicca, M. Manni, E. Bonucci, F. Taggi, Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol. Dial. Transplant. 11, 813–819 (1996)PubMedCrossRef
120.
121.
122.
G. Coen, M. Taccone Gallucci, E. Bonucci, P. Ballanti, A.R. Bianchi, G. Bianchini, M.C. Matteucci, S. Mazzaferro, S. Picca et al., 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone. Miner. Electrolyte Metab. 9, 19–27 (1983)PubMed
123.
124.
125.
B.W. Hollis, C.L. Wagner, Clinical review: The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J. Clin. Endocrinol. Metab. 98, 4619–4628 (2013)PubMedPubMedCentralCrossRef
126.
A.K. Bhalla, E.P. Amento, T.L. Clemens, M.F. Holick, S.M. Krane, Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 57, 1308–1310 (1983)PubMedCrossRef
127.
F. Baeke, T. Takiishi, H. Korf, C. Gysemans, C. Mathieu, Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 10, 482–496 (2010)PubMedCrossRef
128.
129.
R.F. Chun, P.T. Liu, R.L. Modlin, J.S. Adams, M. Hewison, Impact of vitamin D on immune function: lessons learned from genome-wide analysis. Front. Physiol. 5, 151 (2014)PubMedPubMedCentralCrossRef
130.
T. Skaaby, L.L.N. Husemoen, B.H. Thuesen, A. Linneberg, Prospective population-based study of the association between vitamin D status and incidence of autoimmune disease. Endocrine 50, 231–238 (2015)PubMedCrossRef
131.
M. Rossini, S. Maddali Bongi, G. La Montagna, G. Minisola, N. Malavolta, L. Bernini, E. Cacace, L. Sinigaglia, O. Di Munno et al., Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res. Ther. 12, R216 (2010)PubMedPubMedCentralCrossRef
132.
M. Rossini, D. Gatti, O. Viapiana, C. Caimmi, L. Idolazzi, E. Fracassi, S. Adami, Vitamin D and rheumatic diseases. Reumatismo 66, 153–170 (2014)PubMedCrossRef
133.
J. Bogaczewicz, A. Sysa-Jedrzejowska, C. Arkuszewska, J. Zabek, E. Kontny, D. McCauliffe, A. Wozniacka, Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters. Lupus 21, 477–484 (2012)PubMedCrossRef
134.
E. Cutillas-Marco, M. Morales-Suárez-Varela, A. Marquina-Vila, W. Grant, Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 19, 810–814 (2010)PubMedPubMedCentralCrossRef
135.
L.H. Damanhouri, Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Med. J. 30, 1291–1295 (2009)PubMed
136.
R.T. Hamza, K.S. Awwad, M.K. Ali, A.I. Hamed, Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Med. Sci. Monit. 17, CR711–CR718 (2011)PubMedPubMedCentralCrossRef
137.
G. Heine, A. Lahl, C. Müller, M. Worm, Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br. J. Dermatol. 163, 863–865 (2010)PubMedCrossRef
138.
H.-A. Kim, J.-M. Sung, J.-Y. Jeon, J.-M. Yoon, C.-H. Suh, Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol. Int. 31, 1189–1194 (2011)PubMedCrossRef
139.
J. Muñoz-Ortego, V. Torrente-Segarra, D. Prieto-Alhambra, T.C. Salman-Monte, J. Carbonell-Abello, Prevalence and predictors of vitamin D deficiency in non-supplemented women with systemic lupus erythematosus in the Mediterranean region: a cohort study. Scand. J. Rheumatol. 41, 472–475 (2012)PubMedCrossRef
140.
M. Souto, A. Coelho, C. Guo, L. Mendonça, S. Argolo, J. Papi, M. Farias, Vitamin D insufficiency in Brazilian patients with SLE: prevalence, associated factors, and relationship with activity. Lupus 20, 1019–1026 (2011)PubMedCrossRef
141.
G. Gilkeson, J. James, D. Kamen, T. Knackstedt, D. Maggi, A. Meyer, N. Ruth, The United States to Africa lupus prevalence gradient revisited. Lupus 20, 1095–1103 (2011)PubMedPubMedCentralCrossRef
142.
Y.H. Lee, S.-C. Bae, S.J. Choi, J.D. Ji, G.G. Song, Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol. Biol. Rep. 38, 3643–3651 (2011)PubMedCrossRef
143.
X.-Y. Luo, M.-H. Yang, F.-X. Wu, L.-J. Wu, L. Chen, Z. Tang, N.-T. Liu, X.-F. Zeng, J.-L. Guan et al., Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population. Lupus 21, 53–59 (2012)PubMedCrossRef
144.
L.L. Ritterhouse, S.R. Crowe, T.B. Niewold, D.L. Kamen, S.R. Macwana, V.C. Roberts, A.B. Dedeke, J.B. Harley, R.H. Scofield et al., Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 70, 1569–1574 (2011)PubMedPubMedCentralCrossRef
145.
P. Szodoray, T. Tarr, A. Bazso, G. Poor, G. Szegedi, E. Kiss, The immunopathological role of vitamin D in patients with SLE: data from a single center registry in Hungary. Scand. J. Rheumatol. 40, 122–126 (2011)PubMedCrossRef
146.
C.C. Mok, D.J. Birmingham, L.Y. Ho, L.A. Hebert, H. Song, B.H. Rovin, Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus 21, 36–42 (2012)PubMedCrossRef
147.
C.C. Mok, D.J. Birmingham, H.W. Leung, L.A. Hebert, H. Song, B.H. Rovin, Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology 51, 644–652 (2012)PubMedCrossRef
148.
S.S. Yeap, A.Z. Othman, A.A. Zain, S.P. Chan, Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int. J. Rheum. Dis 15, 17–24 (2012)PubMedCrossRef
149.
Z.S. Bonakdar, L. Jahanshahifar, F. Jahanshahifar, A. Gholamrezaei, Vitamin D deficiency and its association with disease activity in new cases of systemic lupus erythematosus. Lupus 20, 1155–1160 (2011)PubMedCrossRef
150.
H. Amital, Z. Szekanecz, G. Szücs, K. Dankó, E. Nagy, T. Csépány, E. Kiss, J. Rovensky, A. Tuchynova et al., Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann. Rheum. Dis. 69, 1155–1157 (2010)PubMedCrossRef
151.
S.M.A. Toloza, D.E.C. Cole, D.D. Gladman, D. Ibañez, M.B. Urowitz, Vitamin D insufficiency in a large female SLE cohort. Lupus 19, 13–19 (2010)PubMedCrossRef
152.
T.B. Wright, J. Shults, M.B. Leonard, B.S. Zemel, J.M. Burnham, Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J. Pediatr. 155, 260–265 (2009)PubMedCrossRef
153.
C.B. Casella, L.P.C. Seguro, L. Takayama, D. Medeiros, E. Bonfa, R.M.R. Pereira, Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health. Lupus 21, 1335–1342 (2012)PubMedCrossRef
154.
A.B. Robinson, M. Thierry-Palmer, K.L. Gibson, C.E. Rabinovich, Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J. Pediatr. 160, 297–302 (2012)PubMedCrossRef
155.
I. Ben-Zvi, C. Aranow, M. Mackay, A. Stanevsky, D.L. Kamen, L.M. Marinescu, C.E. Collins, G.S. Gilkeson, B. Diamond et al., The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One 5, e9193 (2010)PubMedPubMedCentralCrossRef
156.
M. Mandal, R. Tripathy, A.K. Panda, S.S. Pattanaik, S. Dakua, A.K. Pradhan, S. Chakraborty, B. Ravindran, B.K. Das, Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res. Ther. 16, R49 (2014)PubMedPubMedCentralCrossRef
157.
D.J. Birmingham, L.A. Hebert, H. Song, W.T. Noonan, B.H. Rovin, H.N. Nagaraja, C.Y. Yu, Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus 21, 855–864 (2012)PubMedCrossRef
158.
L. Schneider, A.S.P. Dos Santos, M. Santos, R.M. da Silva Chakr, O.A. Monticielo, Vitamin D and systemic lupus erythematosus: state of the art. Clin. Rheumatol. 33, 1033–1038 (2014)PubMed
159.
M. Petri, K.J. Bello, H. Fang, L.S. Magder, Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 65, 1865–1871 (2013)PubMedPubMedCentralCrossRef
160.
C.A. Keyzer, I.J. Riphagen, M.M. Joosten, G. Navis, A.C. Muller Kobold, I.P. Kema, S.J.L. Bakker, M.H. de Borst; NIGRAM consortium, Associations of 25(OH) and 1,25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J. Clin. Endocrinol. Metab. 100, 81–89 (2015)PubMedCrossRef
161.
W.G. Douthat, C.R. Chiurchiu, P.U. Massari, New options for the management of hyperparathyroidism after renal transplantation. World J. Transplant. 2, 41–45 (2012)PubMedPubMedCentralCrossRef
162.
R.W. Steiner, M. Ziegler, N.A. Halasz, B.D. Catherwood, S. Manolagas, L.J. Deftos, Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 56, 843–846 (1993)PubMedCrossRef
163.
K.M. Wissing, N. Broeders, R. Moreno-Reyes, C. Gervy, B. Stallenberg, D. Abramowicz, A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 79, 108–115 (2005)PubMedCrossRef
164.
M. Courbebaisse, C. Alberti, S. Colas, D. Prié, J.-C. Souberbielle, J.-M. Treluyer, E. Thervet, VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial. Trials 15, 430 (2014)PubMedPubMedCentralCrossRef
165.
A. Stavroulopoulos, M.J.D. Cassidy, C.J. Porter, D.J. Hosking, S.D. Roe, Vitamin D status in renal transplant recipients. Am. J. Transplant. 7, 2546–2552 (2007)PubMedCrossRef
166.
G. Cianciolo, A. Galassi, I. Capelli, M.L. Angelini, G. La Manna, M. Cozzolino, Vitamin D in kidney transplant recipients: mechanisms and therapy. Am. J. Nephrol. 43, 397–407 (2016)PubMedCrossRef
167.
K.L. Naylor, A.H. Li, N.N. Lam, A.B. Hodsman, S.A. Jamal, A.X. Garg, Fracture risk in kidney transplant recipients: a systematic review. Transplantation 95, 1461–1470 (2013)PubMedCrossRef
168.
K.L. Naylor, S.A. Jamal, G. Zou, E. McArthur, N.N. Lam, W.D. Leslie, A.B. Hodsman, S.J. Kim, G.A. Knoll et al., Fracture incidence in adult kidney transplant recipients. Transplantation 100, 167–175 (2016)PubMedCrossRef
169.
S. Giannini, S. Sella, F. Silva Netto, C. Cattelan, L. Dalle Carbonare, R. Lazzarin, F. Marchini, P. Rigotti, C. Marcocci et al., Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J. Bone Miner. Res. 25, 841–848 (2010)PubMed
170.
H.M. Alshayeb, M.A. Josephson, S.M. Sprague, CKD-mineral and bone disorder management in kidney transplant recipients. Am. J. Kidney Dis. 61, 310–325 (2013)PubMedCrossRef
171.
A.M. Ball, D.L. Gillen, D. Sherrard, N.S. Weiss, S.S. Emerson, S.L. Seliger, B.R. Kestenbaum, C. Stehman-Breen, Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288, 3014–3018 (2002)PubMedCrossRef
172.
K.C. Abbott, R.J. Oglesby, I.O. Hypolite, A.D. Kirk, C.W. Ko, P.G. Welch, L.Y. Agodoa, W.E. Duncan, Hospitalizations for fractures after renal transplantation in the United States. Ann. Epidemiol. 11, 450–457 (2001)PubMedCrossRef
173.
S. Epstein, Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J. Bone Miner. Res. 11, 1–7 (1996)PubMedCrossRef
174.
S. Giannini, A. D’Angelo, M. Nobile, G. Carraro, P. Rigotti, F. Silva-Netto, S. Pavan, F. Marchini, M. Zaninotto et al., The effects of vitamin D receptor polymorphism on secondary hyperparathyroidism and bone density after renal transplantation. J. Bone Miner. Res. 17, 1768–1773 (2002)PubMedCrossRef
175.
G. Dumoulin, B. Hory, N.U. Nguyen, C. Bresson, V. Fournier, M. Bouhaddi, J.M. Chalopin, Y. Saint-Hillier, J. Regnard, No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am. J. Kidney Dis. 29, 746–753 (1997)PubMedCrossRef
176.
P. Messa, C. Sindici, G. Cannella, V. Miotti, A. Risaliti, M. Gropuzzo, P.L. Di Loreto, F. Bresadola, G. Mioni, Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int. 54, 1704–1713 (1998)PubMedCrossRef
177.
M. Wolf, M.R. Weir, N. Kopyt, R.B. Mannon, J. Von Visger, H. Deng, S. Yue, F. Vincenti, A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation 100, 184–193 (2016)PubMedCrossRef
178.
J. Heaf, E. Tvedegaard, I.-L. Kanstrup, N. Fogh-Andersen, Hyperparathyroidism and long-term bone loss after renal transplantation. Clin. Transplant. 17, 268–274 (2003)PubMedCrossRef
179.
P. Perrin, S. Caillard, R.M. Javier, L. Braun, F. Heibel, C. Borni-Duval, C. Muller, J. Olagne, B. Moulin, Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am. J. Transplant. 13, 2653–2663 (2013)PubMedCrossRef
180.
P. Evenepoel, Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin. Nephrol. 33, 191–203 (2013)PubMedCrossRef
181.
Y.F.C. Smets, J.W. de Fijter, J. Ringers, H.H.P.J. Lemkes, N.A.T. Hamdy, Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. Kidney Int. 66, 2070–2076 (2004)PubMedCrossRef
182.
P. Perrin, C. Kiener, R.-M. Javier, L. Braun, N. Cognard, G. Gautier-Vargas, F. Heibel, C. Muller, J. Olagne et al., Recent changes in chronic kidney disease-mineral and bone disorders (CKD-MBD) and associated fractures after kidney transplantation. Transplantation (2016) (from PubMed: Transplantation. 2016 Aug 19. [Epub ahead of print])
183.
M. Trillini, M. Cortinovis, P. Ruggenenti, J. Reyes Loaeza, K. Courville, C. Ferrer-Siles, S. Prandini, F. Gaspari, A. Cannata et al., Paricalcitol for secondary hyperparathyroidism in renal transplantation. J. Am. Soc. Nephrol. JASN 26, 1205–1214 (2015)PubMedCrossRef
184.
J.M. Cruzado, P. Moreno, J.V. Torregrosa, O. Taco, R. Mast, C. Gómez-Vaquero, C. Polo, I. Revuelta, J. Francos et al., A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J. Am. Soc. Nephrol. 27, 2487–2494 (2016)PubMedCrossRef
185.
M.E. Cho, Z. Duan, C.E. Chamberlain, J.C. Reynolds, M.S. Ring, R.B. Mannon, Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant. Proc. 42, 3554–3558 (2010)PubMedPubMedCentralCrossRef
186.
N.C. Boudville, A.B. Hodsman, Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol. Dial. Transplant. 21, 2621–2624 (2006)PubMedCrossRef
187.
K. Querings, M. Girndt, J. Geisel, T. Georg, W. Tilgen, J. Reichrath, 25-hydroxyvitamin D deficiency in renal transplant recipients. J. Clin. Endocrinol. Metab. 91, 526–529 (2006)PubMedCrossRef
188.
D.M. Sadlier, C.C. Magee, Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: a prospective study. Clin. Transplant. 21, 683–688 (2007)PubMed
189.
B. Ewers, A. Gasbjerg, C. Moelgaard, A.M. Frederiksen, P. Marckmann, Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am. J. Clin. Nutr. 87, 431–437 (2008)PubMed
190.
S. Euvrard, J. Kanitakis, A. Claudy, Skin cancers after organ transplantation. N. Engl. J. Med. 348, 1681–1691 (2003)PubMedCrossRef
191.
S.M.H. Rizvi, M.B. Veierød, P.M. Thorsby, P. Helsing, Vitamin D in Norwegian renal transplant recipients: A longitudinal study with repeated measurements in winter and summer. Eur. J. Dermatol. 25, 234–239 (2015)PubMed
192.
U. Thiem, G. Heinze, R. Segel, T. Perkmann, F. Kainberger, F. Mühlbacher, W. Hörl, K. Borchhardt, VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome. Trials 10, 36 (2009)PubMedPubMedCentralCrossRef
193.
S.S. Tripathi, E.M. Gibney, T.W.B. Gehr, A.L. King, M.J. Beckman, High prevalence of vitamin D deficiency in African American kidney transplant recipients. Transplantation 85, 767–770 (2008)PubMedCrossRef
194.
G. Sahin, N.S. Yasar, B. Sirmagul, C. Bal, A.U. Yalcin, The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study. Ren. Fail. 30, 992–999 (2008)PubMedCrossRef
195.
M. Courbebaisse, E. Thervet, J.C. Souberbielle, J. Zuber, D. Eladari, F. Martinez, M.-F. Mamzer-Bruneel, P. Urena, C. Legendre et al., Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int. 75, 646–651 (2009)PubMedCrossRef
196.
X. Barros, N.Y. Rodríguez, D. Fuster, L. Rodas, N. Esforzado, A. Mazza, D. Rubello, F. Campos, A. Tapias et al., Comparison of two different vitamin D supplementation regimens with oral calcifediol in kidney transplant patients. J. Nephrol. 29, 703–709 (2016)PubMedCrossRef
197.
Y. Obi, T. Hamano, N. Ichimaru, K. Tomida, I. Matsui, N. Fujii, M. Okumi, J. Kaimori, K. Yazawa et al., Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study. J. Clin. Endocrinol. Metab. 99, 527–535 (2014)PubMedCrossRef
Metadata
Title
Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion
Authors
Sandro Giannini
Sandro Mazzaferro
Salvatore Minisola
Luca De Nicola
Maurizio Rossini
Mario Cozzolino
Publication date
01-02-2018
Publisher
Springer US
Published in
Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1369-3

Other articles of this Issue 2/2018

Endocrine 2/2018 Go to the issue

Original Article

Effects of chronic endurance exercise training on serum 25(OH)D concentrations in elderly Japanese men

Original Article

Metformin, beta-cell development, and novel processes following beta-cell ablation in zebrafish

Letter to the Editor

Long lasting prophylaxis of iodine deficiency after a successful information campaign for iodized salt consumption

Review

Irisin in metabolic diseases

Original Article

Bone marrow fat contributes to insulin sensitivity and adiponectin secretion in premenopausal women

Endocrine Genetics/Epigenetics

Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits